Sep 30,2019

Brain stimulation headset maker Flow launches mental health chatbot

With the staggering shortage of mental health practitioners worldwide, more and more startups are looking for alternative ways to provide patient care. One of the most popular technologies is chatbots. Now we are seeing one more entrance emerge into that market. On Thursday, Sweden- and UK-based medical device company Flow, best known for its brain stimulation headset, launched a new chatbot aimed at helping to treat depression. According to the company the new technology was designed to engage users in conversation, track mood and meditate. Additionally, users can also use the chatbot to download curated video content.

PRODUCT

#chatbot

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 03,2019

Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder

Otsuka America, Inc., and Click Therapeutics, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder (MDD), with the intent to address unmet medical needs among this patient population and to improve outcomes. This collaboration will leverage Click’s demonstrated ability to discover and validate a software application and deploy it commercially, with Otsuka’s expertise in developing approved prescription therapies for patients with serious mental illnesses, including Otsuka’s established development and commercialization capabilities

COLLABORATION PARTNERSHIP

#r&d

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 08,2019

Omada Health adds mental health program, gives Lantern Health second life

Omada Health will launch new programs for customers with depression and anxiety, the company announced yesterday. The company has entered into a perpetual licensing agreement with Lantern Health, a digital mental health company that shut down its commercial operations last August, and will integrate Lantern’s software into its existing infrastructure. Additionally, a few members of Lantern’s team will work with Omada to develop and deploy the technology.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Jan 24,2019

Stanford, VA Palo Alto Health Care System launch trial of digital depression therapy program

The acceptability, safety, feasibility and preliminary efficacy of Meru Health’s digital therapeutic for depression will be evaluated in a new two-year investigation conducted by Stanford Medicine and VA Palo Alto Health Care System researchers. According to a clinicaltrials.gov listing, the research program will enroll older adults aged at least 40 years with depressive symptoms in two studies.

PRODUCT

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Oct 10,2019

SilverCloud Health Collaborates with Microsoft in Pioneering Artificial Intelligence (AI) Research to Deliver More Effective Digital Mental Healthcare

SilverCloud Health, the world's leading digital mental health company, officially announced its research collaboration with Microsoft to further enhance its online offering with artificial intelligence (AI). SilverCloud Health and Microsoft Labs in Cambridge have been working together over the past 18 months, in research that combines Microsoft's cutting-edge machine learning and AI technologies with SilverCloud's expertise in real-world delivery of evidence-based interventions and mental health outcomes.

COLLABORATION PARTNERSHIP

#r&d

#software

View Analyst & Ambassador Comments
Go to original news
Aug 01,2018

Digital therapeutics are just what the doctor ordered for patients — and for global healthcare systems

It would be hard to argue that digital products have a net-positive impact on our health. The habit-forming power of digital products can be used for therapeutic benefit too, often by changing the behavior that causes disease or ill health. This new range of products is being commonly referred to as digital therapeutics. These apps and services offer evidence-based and personalized behavioral therapy, and cater to a broad cross-section of illnesses and conditions — from diabetes to loneliness, and everything in-between.

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2018

CureApp and HIKARI LAB Begins “ascureSPARX Mental Health Program”

CureApp which deals with the research and development of “Treatment Applications” as medical devices in treatment programs, together with HIKARI LAB Co., Ltd. which offers online counselling and smart phone applications for psychological care, have joined together to begin offering the “ascureSPARX Mental Health Program”. The “ascureSPARX Mental Health Program” is a psychological care and counseling program that combines a “doctor developed application” and “online counseling”.

COLLABORATION PARTNERSHIP

#institution

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 29,2018

Study: Smartphone app effective in treating serious mental illness

A recent study published by Psychiatric Services found that mobile health interventions were as effective in treating patients with serious mental illness compared to an in-person group therapy. The study found that participants in the mobile health group were more likely to remain fully engaged in the eight-week study than those receiving traditional care. Researchers also found that satisfaction rates between the two groups were similar, and that the conditions of participants in both groups improved significantly.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 06,2018

Click Therapeutics Announces Multiple Publications Supporting Its Digital Therapeutic for Major Depressive Disorder

Click Therapeutics announces today multiple publications and presentations of clinical research data supporting its digital therapeutic for major depressive disorder (MDD). The results of a 51-person randomized controlled trial of the Emotional Faces Memory Task (EFMT), a digital therapeutic for MDD, were recently published in npj Digital Medicine, a Nature research journal. This trial found EFMT to be superior to the control group in terms of MDD symptom reduction, and also the proportion of participants meeting “clinical responder” criteria.

CLINICAL STUDY

#software

#pdt

View Analyst & Ambassador Comments
Go to original news
Dec 17,2018

Pear Therapeutics Announces Initiation of Proof of Concept Study for Prescription Digital Therapeutic in Development for the Treatment of Schizophrenia

Pear Therapeutics, Inc. today announced the initiation of a Phase 2, proof of concept study for its prescription digital therapeutic in development for schizophrenia. The treatment, known as Pear-004, is designed to deliver multimodal neurobehavioral interventions to improve symptoms and functioning of people with schizophrenia.

PRODUCT

#mobile app

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH